The formation of ADA has also been identified in AD patient serum in passive immunotherapy trials with crenezumab (an anti-Aβ antibody), tilavonemab (an anti-tau antibody) and solanezumab [13, 17, 35]. The gene discussed is ADA; the disease is Alzheimer disease.